InnoCare Pharma's (HKG:9969) orelabrutinib was approved by the Therapeutic Goods Administration (TGA) in Australia to treat adult patients with relapsed or refractory mantle cell lymphoma, according to a Thursday Hong Kong bourse filing.
Orelabrutinib has been developed by the pharma firm to treat cancers and autoimmune diseases.
L&F Plus took out a loan of 30 billion won from its parent and battery materials producer L&F (KRX:066970) to secure funds for new facility investment, according to a filing with the Korea Exchange on Thursday.The loan period is from May 29 to Dec. 30. The loan amount is equivalent to 4.43% of L&F Plus' total equity capital, it said.Shares of L&F added over 13% at market close.
Samsung Electronics (KRX:005930) and Harvard Medical School affiliate Massachusetts General Hospital (MGH) will jointly track and analyze physical changes in patients taking glucagon-like peptide-1 (GLP-1) class treatments with the help of the Galaxy Watch.GLP-1 is an intestinal hormone that helps regulate blood sugar and suppress appetite, Samsung Electronics said in a Thursday release.The study will assess whether data from the Galaxy Watch 8 and Samsung Health can help manage muscle loss in patients who take GLP-1 drugs by tracking body composition, activity, and heart rate, according to the release.Shares of Samsung Electronics fell over 2% at market close.
LG Display (KRX:034220) began the mass production of 240Hz red, green, and blue (RGB) stripe OLED panels, the display maker said in a Thursday release.The panels are optimized for both gaming and office use, according to the release.The display maker plans to expand its OLED monitor lineup with the mass production of 27-inch models alongside key global brands, with an aim to strengthen its presence in the premium monitor market, it said.Shares of LG Display added over 2% at market close.